2017 Volume 32 Issue 3 Pages 141-147
Although hepatitis B virus (HBV) vaccine shows protective effect against HBV infection, its efficacy when manufactures derived from different antigens (MDA) were used in subsequent doses after the primary series remained unclear.
HBV vaccine of MDA was inoculated in nine health-care workers with both negative hepatitis B surface (HBs) and HBs antibody at the third dose. We then evaluated the immunogenicity.
All participants showed successful seroconversion of anti-HBs antigen to seropositive after 10 months. Adverse events with grade 1 were found in 33% (3/9) and were permissive.
In conclusion, our results suggested that vaccination for HBV was successful even when MDA was used at the third dose for HBV.
